Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
CytoDyn Inc is a biotechnology business based in the US. CytoDyn shares (CYDY) are listed on the OTCQB and all prices are listed in US Dollars. CytoDyn employs 19 staff and has a market cap (total outstanding shares value) of USD$2 billion.
Since the stock market crash in March caused by coronavirus, CytoDyn's share price has had significant positive movement.
Its last market close was USD$3.55, which is 69.15% up on its pre-crash value of USD$1.095 and 349.37% up on the lowest point reached during the March crash when the shares fell as low as USD$0.79.
If you had bought USD$1,000 worth of CytoDyn shares at the start of February 2020, those shares would have been worth USD$642.58 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$2,343.25.
|Latest market close||USD$3.55|
|52-week range||USD$0.263 - USD$8.9|
|50-day moving average||USD$3.9821|
|200-day moving average||USD$3.4982|
|Wall St. target price||USD$4|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.188|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-09-14)||-13.83%|
|1 month (2020-08-21)||3.50%|
|3 months (2020-06-19)||-3.53%|
|6 months (2020-03-20)||273.68%|
|1 year (2019-09-20)||810.96%|
|2 years (2018-09-21)||531.67%|
|3 years (2017-09-21)||447.00%|
|5 years (2015-09-21)||355.42%|
|Gross profit TTM||USD$0|
|Return on assets TTM||-130.71%|
|Return on equity TTM||0%|
|Market capitalisation||USD$2 billion|
TTM: trailing 12 months
We're not expecting CytoDyn to pay a dividend over the next 12 months.
Over the last 12 months, CytoDyn's shares have ranged in value from as little as $0.263 up to $8.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (OTCQB average) beta is 1, while CytoDyn's is -1.0697. This would suggest that CytoDyn's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, CytoDyn has bucked the trend.
CytoDyn Inc., a late-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies to treat human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb extension study for HIV as monotherapy, rollover study for HIV as a combination therapy, Phase IIb/III investigative trial for HIV, Phase Ib/II trial for triple-negative breast cancer, and Phase II trial for graft-versus-host disease. CytoDyn Inc. has strategic agreement with Samsung BioLogics Co. Ltd. for the clinical and commercial manufacturing of leronlimab. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.